Subventions et des contributions :

Retour à la page de recherche
Titre :
Chemical biosensors for improving drug production
Numéro de l’entente :
EGP
Valeur d'entente :
25 000,00 $
Date d'entente :
10 janv. 2018 -
Organisation :
Conseil de recherches en sciences naturelles et en génie du Canada
Location :
Ontario, Autre, CA
Numéro de référence :
GC-2017-Q4-01223
Type d'entente :
subvention
Type de rapport :
Subventions et des contributions
Informations supplémentaires :

Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier (2017-2018 à 2018-2019).

Nom légal du bénéficiaire :
McMillen, David (University of Toronto)
Programme :
Subventions d'engagement partenarial pour les universités
But du programme :

Many pharmaceuticals are complex, natural compounds that can be difficult to extract from their sources or tox000D
synthesize chemically. To overcome this, some pharmaceuticals can be produced in a host organism that isx000D
easier to manage on a commercial scale. Hyasynth Bio has developed strains of yeast that producex000D
cannabinoids, a class of compounds with great potential as medicines and therapeutics. Early approvedx000D
cannabinoid medicines in Canada include nabiximols, for adjunctive analgesic treatment in adult patients withx000D
advanced cancer, and nabilone, for severe nausea and vomiting associated with cancer chemotherapy. Tox000D
rapidly screen yeast strains with improved cannabinoid production, a simple way of detecting and quantifyingx000D
these compounds is required. We aim to develop a new means of detecting medicinal cannabinoids to improvex000D
their commercial production.

"Détails de la page"